Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015, Article ID 703218, 7 pages
http://dx.doi.org/10.1155/2015/703218
Case Report

Clozapine-Induced Late Agranulocytosis and Severe Neutropenia Complicated with Streptococcus pneumonia, Venous Thromboembolism, and Allergic Vasculitis in Treatment-Resistant Female Psychosis

13rd Department of Internal Medicine, Athens General Regional Hospital “G. Gennimatas”, Mesogeion Avenue 154, 115 27 Athens, Greece
2Flow Cytometry Laboratory, Department of Immunology, Athens General Regional Hospital “G. Gennimatas”, Athens, Greece
3Department of Hematology, Athens General Regional Hospital “G. Gennimatas”, Athens, Greece

Received 10 November 2014; Accepted 27 January 2015

Academic Editor: B. Carpiniello

Copyright © 2015 Christina Voulgari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. McEvoy, J. A. Lieberman, T. S. Stroup et al., “Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment,” The American Journal of Psychiatry, vol. 163, no. 4, pp. 600–610, 2006. View at Google Scholar · View at Scopus
  2. E. Whiskey and D. Taylor, “Restarting clozapine after neutropenia: evaluating the possibilities and practicalities,” CNS Drugs, vol. 21, no. 1, pp. 25–35, 2007. View at Google Scholar · View at Scopus
  3. N. Blieden, S. Flinders, K. Hawkins, M. Reid, L. D. Alphs, and C. L. Arfken, “Health status and health care costs for publicly funded patients with schizophrenia started on clozapine,” Psychiatric Services, vol. 49, no. 12, pp. 1590–1593, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Y. Meltzer, L. Alphs, A. I. Green et al., “Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT),” Archives of General Psychiatry, vol. 60, no. 1, pp. 82–91, 2003. View at Google Scholar
  5. P. B. Mitchell, G. M. Goodwin, G. F. Johnson, and R. M. A. Hirschfeld, “Diagnostic guidelines for bipolar depression: a probabilistic approach,” Bipolar Disorders, vol. 10, no. 1, part 2, pp. 144–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. H. Perlis, M. J. Ostacher, J. K. Patel et al., “Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD),” The American Journal of Psychiatry, vol. 163, no. 2, pp. 217–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. C. D. Schneck, D. J. Miklowitz, S. Miyahara et al., “The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD,” The American Journal of Psychiatry, vol. 165, no. 3, pp. 370–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. W. Woods, “The economic burden of bipolar disease,” The Journal of Clinical Psychiatry, vol. 61, supplement 13, pp. 38–41, 2000. View at Google Scholar · View at Scopus
  9. A. K. Das, M. Olfson, M. J. Gameroff et al., “Screening for bipolar disorder in a primary care practice,” Journal of the American Medical Association, vol. 293, no. 8, pp. 956–963, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Matte, L. A. Rohde, and E. H. Grevet, “ADHD in adults: a concept in evolution,” ADHD Attention Deficit and Hyperactivity Disorders, vol. 4, no. 2, pp. 53–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. J. Alvir, J. A. Lieberman, A. Z. Safferman, J. L. Schwimmer, and J. A. Schaaf, “Clozapine-induced agranulocytosis: incidence and risk factors in the United States,” The New England Journal of Medicine, vol. 329, no. 3, pp. 162–167, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Hummer, M. Kurz, C. Barnas, A. Saria, and W. W. Fleischhacker, “Clozapine-induced transient white blood count disorders,” The Journal of Clinical Psychiatry, vol. 55, no. 10, pp. 429–432, 1994. View at Google Scholar
  13. A. Ahokas and E. Elonen, “Circadian rhythm of white blood cells during clozapine treatment,” Psychopharmacology, vol. 144, no. 3, pp. 301–302, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Flanagan and L. Dunk, “Haematological toxicity of drugs used in psychiatry,” Human Psychopharmacology, vol. 23, supplement 1, pp. S27–S41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. L. Gerson, “Clozapine—deciphering the risks,” The New England Journal of Medicine, vol. 329, no. 3, pp. 204–205, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. N. C. Patel, P. G. Dorson, and T. L. Bettinger, “Sudden late onset of clozapine-induced agranulocytosis,” The Annals of Pharmacotherapy, vol. 36, no. 6, pp. 1012–1015, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. A. G. Freifeld, E. J. Bow, K. A. Sepkowitz et al., “Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America,” Clinical Infectious Diseases, vol. 52, no. 4, pp. e56–e93, 2011. View at Publisher · View at Google Scholar
  18. K. Atkin, F. Kendall, D. Gould, H. Freeman, J. Lieberman, and D. O'Sullivan, “Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland,” The British Journal of Psychiatry, vol. 169, no. 4, pp. 483–488, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. S. L. Gerson and H. Meltzer, “Mechanisms of clozapine-induced agranulocytosis.,” Drug Safety, vol. 7, no. 1, supplement, pp. 17–25, 1992. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Munro, D. O'Sullivan, C. Andrews, A. Arana, A. Mortimer, and R. Kerwin, “Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance,” The British Journal of Psychiatry, vol. 175, pp. 576–580, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Opgen-Rhein and M. Dettling, “Clozapine-induced agranulocytosis and its genetic determinants,” Pharmacogenomics, vol. 9, no. 8, pp. 1101–1111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Athanasiou, M. Dettling, I. Cascorbi et al., “Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis,” The Journal of Clinical Psychiatry, vol. 72, no. 4, pp. 458–463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Andrès and F. Maloisel, “Idiosyncratic drug-induced agranulocytosis or acute neutropenia,” Current Opinion in Hematology, vol. 15, no. 1, pp. 15–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Manu, D. Sarpal, O. Muir, J. M. Kane, and C. U. Correll, “When can patients with potentially lifethreatening adverse effects be rechallenged with clozapine? A systematic review of the published literature,” Schizophrenia Research, vol. 134, no. 2-3, pp. 180–186, 2012. View at Publisher · View at Google Scholar
  25. M. P. K. Crews, G. S. Dhillon, and J. H. MacCabe, “Clozapine rechallenge following clozapine-induced pericarditis,” The Journal of Clinical Psychiatry, vol. 71, no. 7, pp. 959–961, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. K. DasGupta and A. Young, “Clozapine-induced neuroleptic malignant syndrome,” The Journal of Clinical Psychiatry, vol. 52, no. 3, pp. 105–107, 1991. View at Google Scholar · View at Scopus
  27. B. Sperner-Unterweger, I. Czeipek, S. Gaggl, D. Geissler, G. Spiel, and W. W. Fleischhacker, “Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF): remission despite continuous treatment with clozapine,” The British Journal of Psychiatry, vol. 172, pp. 82–84, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Esposito, F. Rouillon, and F. Limosin, “Continuing clozapine treatment despite neutropenia,” European Journal of Clinical Pharmacology, vol. 60, no. 11, pp. 759–764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. K. N. R. Chengappa, A. Gopalani, M. K. Haught, K. McChesney, R. W. Baker, and N. R. Schooler, “The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF),” Psychopharmacology Bulletin, vol. 32, no. 1, pp. 111–121, 1996. View at Google Scholar · View at Scopus
  30. D. Esposito, P. Hardy, and E. Corruble, “Clozapine treatment following blood dyscrasia,” The British Journal of Psychiatry, vol. 189, article 186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Ghaznavi, M. Nakic, P. Rao et al., “Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia,” The American Journal of Psychiatry, vol. 165, no. 7, pp. 813–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Taylor, C. Paton, and S. Kapur, The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines, Informa Healthcare, 10th edition, 2009.
  33. L. R. Dunk, L. J. Annan, and C. D. Andrews, “Rechallenge with clozapine following leucopenia or neutropenia during previous therapy,” The British Journal of Psychiatry, vol. 188, pp. 255–263, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. S.-Y. Wu, C.-C. Liu, and M. H. Hsieh, “Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 4, pp. 1089–1090, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Dernovsek and R. Tavcar, “Risperidone-induced leucopenia and neutropenia,” The British Journal of Psychiatry, vol. 171, no. 4, pp. 393–394, 1997. View at Publisher · View at Google Scholar
  36. P. Thangadurai, K. S. Jyothi, R. Gopalakrishnan, A. Kuruvilla, and K. S. Jacob, “Reversible neutropenia with olanzapine following clozapine-induced neutropenia,” The American Journal of Psychiatry, vol. 163, no. 7, p. 1298, 2006. View at Google Scholar · View at Scopus
  37. S. Hägg, O. Spigset, and T. G. Söderström, “Association of venous thromboembolism and clozapine,” The Lancet, vol. 355, no. 9210, pp. 1155–1156, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. A. K. Jönsson, O. Spigset, and S. Hägg, “Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management,” CNS Drugs, vol. 26, no. 8, pp. 649–662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. C. A. Paciullo, “Evaluating the association between clozapine and venous thromboembolism,” The American Journal of Health-System Pharmacy, vol. 65, no. 19, pp. 1825–1829, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Hägg, A. K. Jönsson, and O. Spigset, “Risk of venous thromboembolism due to antipsychotic drug therapy,” Expert Opinion on Drug Safety, vol. 8, no. 5, pp. 537–547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. K. M. Penaskovic, S. Annamraju, and J. E. Kraus, “Clozapine-induced allergic vasculitis,” The American Journal of Psychiatry, vol. 162, no. 8, p. 1543, 2005. View at Publisher · View at Google Scholar · View at Scopus